• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全身免疫炎症指数在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的预后价值:一项系统评价和荟萃分析

Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

作者信息

Chen Guorong, Bao Bahu, Ye Yucai, Hu Aoyan, Sun Jingzi, Liu Weiying

机构信息

Department of Respiratory Medicine, The First Clinical Medical College of Lanzhou University, Lanzhou, China.

Department of Respiratory and Critical Care Medicine, the First Hospital of Lanzhou University, Lanzhou, Gansu, China.

出版信息

Front Oncol. 2025 May 16;15:1532343. doi: 10.3389/fonc.2025.1532343. eCollection 2025.

DOI:10.3389/fonc.2025.1532343
PMID:40452837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12122344/
Abstract

BACKGROUND

Although the systemic immune-inflammation index (SII) has emerged as a potential prognostic marker in various cancers, its specific role in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy remains insufficiently explored. To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors (ICIs).

METHOD

A comprehensive search was conducted across multiple databases-including PubMed, EMBASE, Cochrane and Web of Science-to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of SII for survival outcomes.

RESULT

Ten studies involving a total of 1,547 patients were included. High systemic immune-inflammation index (SII) was significantly associated with worse overall survival (OS) (HR=1.44, 95% CI=1.21-1.70, p < 0.001; I²=3.8%) and progression-free survival (PFS) (HR=1.44, 95% CI=1.21-1.71, p < 0.001; I²=37.2%). Subgroup analysis indicated that an SII >792 was significantly associated with poorer OS and PFS.

CONCLUSION

High SII is significantly associated with poorer OS and PFS, particularly when SII >792.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586791, identifier RD42024586791.

摘要

背景

尽管全身免疫炎症指数(SII)已成为各种癌症潜在的预后标志物,但其在接受免疫治疗的非小细胞肺癌(NSCLC)患者中的具体作用仍未得到充分探索。为了填补这一关键空白,我们进行了一项全面的荟萃分析,以评估SII在接受免疫检查点抑制剂(ICI)治疗的NSCLC患者中的预后价值。

方法

在多个数据库(包括PubMed、EMBASE、Cochrane和Web of Science)中进行全面检索,以识别相关研究。汇总风险比(HR)和95%置信区间(CI),以评估SII对生存结局的预后意义。

结果

纳入了10项研究,共1547例患者。高全身免疫炎症指数(SII)与较差的总生存期(OS)(HR=1.44,95%CI=1.21-1.70,p<0.001;I²=3.8%)和无进展生存期(PFS)(HR=1.44,95%CI=1.21-1.71,p<0.001;I²=37.2%)显著相关。亚组分析表明,SII>792与较差的OS和PFS显著相关。

结论

高SII与较差的OS和PFS显著相关,尤其是当SII>792时。

系统评价注册

https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586791,标识符RD42024586791。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/2a2acd18bb71/fonc-15-1532343-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/febfdb368661/fonc-15-1532343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/9a2f6d8b2bbb/fonc-15-1532343-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/f16280972a7d/fonc-15-1532343-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/53ceeff1ab2e/fonc-15-1532343-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/817f4e071d82/fonc-15-1532343-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/2a2acd18bb71/fonc-15-1532343-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/febfdb368661/fonc-15-1532343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/9a2f6d8b2bbb/fonc-15-1532343-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/f16280972a7d/fonc-15-1532343-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/53ceeff1ab2e/fonc-15-1532343-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/817f4e071d82/fonc-15-1532343-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4460/12122344/2a2acd18bb71/fonc-15-1532343-g006.jpg

相似文献

1
Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.全身免疫炎症指数在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的预后价值:一项系统评价和荟萃分析
Front Oncol. 2025 May 16;15:1532343. doi: 10.3389/fonc.2025.1532343. eCollection 2025.
2
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗胃癌患者中炎症标志物 NLR、PLR 和 LMR 的预后价值:荟萃分析和系统评价。
Front Immunol. 2024 Jul 10;15:1408700. doi: 10.3389/fimmu.2024.1408700. eCollection 2024.
3
Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: A systematic review and meta-analysis.全身免疫炎症指数作为接受免疫检查点抑制治疗的非小细胞肺癌患者生存的预测指标:一项系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2025 Jun;210:104669. doi: 10.1016/j.critrevonc.2025.104669. Epub 2025 Feb 18.
4
Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma.术前全身免疫炎症指数作为尿路上皮癌患者的预后指标。
Front Immunol. 2023 Nov 20;14:1275033. doi: 10.3389/fimmu.2023.1275033. eCollection 2023.
5
High systemic immune-inflammation index predicts poor prognosis and response to intravesical BCG treatment in patients with urothelial carcinoma: a systematic review and meta-analysis.高全身免疫炎症指数预示着尿路上皮癌患者的预后不良及对膀胱内卡介苗治疗的反应:一项系统评价和荟萃分析。
Front Oncol. 2023 Nov 1;13:1229349. doi: 10.3389/fonc.2023.1229349. eCollection 2023.
6
Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis.全身免疫炎症指数在接受全身治疗的转移性肾细胞癌患者中的预后价值:一项荟萃分析
Front Oncol. 2024 Jun 19;14:1404753. doi: 10.3389/fonc.2024.1404753. eCollection 2024.
7
Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗黑色素瘤患者中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、淋巴细胞与单核细胞比值、中性粒细胞与淋巴细胞比值差值、嗜中性粒细胞计数的预后价值:荟萃分析和系统评价。
Front Immunol. 2024 Oct 18;15:1482746. doi: 10.3389/fimmu.2024.1482746. eCollection 2024.
8
Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis.全身免疫炎症指数在鼻咽癌患者中的预后意义:一项荟萃分析
Syst Rev. 2022 Nov 19;11(1):247. doi: 10.1186/s13643-022-02123-y.
9
Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.血小板与淋巴细胞比值(PLR)在接受免疫治疗的晚期肺癌患者临床结局中的预后作用:一项系统评价和荟萃分析。
Front Oncol. 2022 Aug 22;12:962173. doi: 10.3389/fonc.2022.962173. eCollection 2022.
10
Prognostic value of systemic immune-inflammation index for patients undergoing radical prostatectomy: a systematic review and meta-analysis.根治性前列腺切除术患者全身免疫炎症指数的预后价值:一项系统评价和荟萃分析
Front Immunol. 2025 Feb 4;16:1465971. doi: 10.3389/fimmu.2025.1465971. eCollection 2025.

本文引用的文献

1
Biomarkers for immunotherapy resistance in non-small cell lung cancer.非小细胞肺癌免疫治疗耐药的生物标志物
Front Oncol. 2024 Dec 19;14:1489977. doi: 10.3389/fonc.2024.1489977. eCollection 2024.
2
Comparison of Prognostic Values of Seven Immune Indexes in Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab: How Effective Can They Be Regarding Our Treatment Decisions?比较纳武利尤单抗治疗晚期非小细胞肺癌的七种免疫指标的预后价值:它们对我们的治疗决策有多大效果?
Medicina (Kaunas). 2024 Nov 1;60(11):1792. doi: 10.3390/medicina60111792.
3
Neutrophils in Cancer immunotherapy: friends or foes?
中性粒细胞在癌症免疫治疗中的作用:是敌是友?
Mol Cancer. 2024 May 18;23(1):107. doi: 10.1186/s12943-024-02004-z.
4
Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.联合预处理中性粒细胞-淋巴细胞比值和血小板-淋巴细胞比值预测非转移性鼻咽癌患者的生存和预后:一项回顾性研究。
Sci Rep. 2024 Apr 30;14(1):9898. doi: 10.1038/s41598-024-59131-2.
5
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
6
The dynamic role of platelets in cancer progression and their therapeutic implications.血小板在癌症进展中的动态作用及其治疗意义。
Nat Rev Cancer. 2024 Jan;24(1):72-87. doi: 10.1038/s41568-023-00639-6. Epub 2023 Dec 1.
7
Exploiting innate immunity for cancer immunotherapy.利用先天免疫进行癌症免疫治疗。
Mol Cancer. 2023 Nov 27;22(1):187. doi: 10.1186/s12943-023-01885-w.
8
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.炎症与营养指数对纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌的疗效预测价值
Oncology. 2024;102(3):271-282. doi: 10.1159/000534169. Epub 2023 Sep 19.
9
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.放化疗后接受度伐鲁单抗巩固治疗的非小细胞肺癌患者中改良格拉斯哥预后评分和持续炎症的预测价值:一项多中心回顾性研究
Cancers (Basel). 2023 Sep 1;15(17):4358. doi: 10.3390/cancers15174358.
10
Assessing the role of colonic and other anatomical sites uptake by [ F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors.评估 [ F]FDG-PET/CT 检测结直肠和其他解剖部位摄取以及免疫炎症性外周血指标在一线免疫检查点抑制剂治疗晚期非小细胞肺癌患者中的作用。
Thorac Cancer. 2023 Aug;14(24):2473-2483. doi: 10.1111/1759-7714.15032. Epub 2023 Jul 13.